S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet

Adaptimmune Therapeutics (ADAP) Stock Forecast & Price Target

$1.59
+0.02 (+1.27%)
(As of 03/1/2024 ET)

Adaptimmune Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 3 Analyst Ratings

Analysts' Consensus Price Target

$4.65
192.45% Upside
High Forecast$10.00
Average Forecast$4.65
Low Forecast$1.00
TypeCurrent Forecast
3/3/23 to 3/2/24
1 Month Ago
2/1/23 to 2/1/24
3 Months Ago
12/3/22 to 12/3/23
1 Year Ago
3/3/22 to 3/3/23
Consensus Rating
Hold
Hold
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.65$4.65$4.65$6.00
Predicted Upside192.45% Upside331.41% Upside313.10% Upside210.88% Upside
Get Adaptimmune Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.


ADAP Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ADAP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Adaptimmune Therapeutics Stock vs. The Competition

TypeAdaptimmune TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.68
2.48
Consensus RatingHoldModerate BuyHold
Predicted Upside192.45% Upside1,799.15% Upside6.76% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/10/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$5.00 ➝ $4.00+378.98%
8/10/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$2.00 ➝ $1.00+17.65%
4/17/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$10.00+606.71%
3/24/2023Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$3.60+230.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:12 PM ET.












ADAP Price Target - Frequently Asked Questions

What is Adaptimmune Therapeutics's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Adaptimmune Therapeutics stock is Hold based on the current 1 sell rating and 2 buy ratings for ADAP. The average twelve-month price prediction for Adaptimmune Therapeutics is $4.65 with a high price target of $10.00 and a low price target of $1.00. Learn more on ADAP's analyst rating history.

Do Wall Street analysts like Adaptimmune Therapeutics more than its competitors?

Analysts like Adaptimmune Therapeutics less than other Medical companies. The consensus rating for Adaptimmune Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how ADAP compares to other companies.

Does Adaptimmune Therapeutics's stock price have much upside?

According to analysts, Adaptimmune Therapeutics's stock has a predicted upside of 331.41% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NASDAQ:ADAP) was last updated on 3/2/2024 by MarketBeat.com Staff